VIMTALABS

- Concall Schedule - Meeting 1: September 04, 2026, 11:00 AM (IST) with Mr. Lukas Davies (Oppenheimer Generations Asia) - Physical Meeting. - Meeting 2: September 09, 2026, 04:00 PM (IST) with Mr. Karan Doshi (Abakkus Asset Management) - Virtual Meeting. - No unpublished price sensitive information will be shared.

- Analyst/Institutional Investor Meetings Scheduled: - Meeting with Mr. Lukas Davies (Oppenheimer Generations Asia) on 04th September 2026 at 11:00 A.M (IST) (Physical Meeting). - Meeting with Mr. Karan Doshi (Abakkus Asset Management) on 09th September 2026 at 04:00 P.M (IST) (Virtual Meeting). - No unpublished price sensitive information will be shared in these meetings.

- Vimta Labs Limited detected a cyber security incident affecting a part of its IT infrastructure. - The company initiated containment measures and engaged external cybersecurity experts. - Operations and customer delivery services have remained fully functional with no material impact identified on operations thus far.

- Investor/Analyst Meet Schedule - Meeting Date: 31st July 2026 - Type: Virtual One-on-One meetings with Ms. Pragati Khadse (Nine Rivers Capital) and Mr. Avnish Tiwari & Mr. Avnish Burman (Vaikarya Change). - Agenda: To understand company's business operations.

- Analyst/Institutional Investor Meets Scheduled - Date: July 31, 2026 - Meeting 1: 03:30 P.M - 04:30 P.M (IST) with Ms. Pragati Khadse (Nine Rivers Capital) - Meeting 2: 04:30 P.M - 05:30 P.M (IST) with Mr. Avnish Tiwari & Mr. Avnish Burman (Vaikarya Change) - Agenda: To understand company's business operations.

- Management reiterated an aspiration for 20-25% growth for FY27, despite some Q1 challenges in the food and environment business due to global issues. - Q1 FY27 Total Income grew by 13.7% YoY to INR1,129 million. - EBITDA increased by 16% YoY to INR411 million, and PAT grew by 11.4% YoY to INR210 million. - EBITDA margins for Q1 FY27 stood at 36.4%, showing YoY improvement, and PAT margins at 18.6%. - The company secured its first order for Biologics services and operationalized the facility, with commercialization starting in Q1, expecting significant contribution from the third year onwards. - FY27 Capex budget is approximately INR80 crores, including INR10 crores for Biologics CRADs, aimed at strengthening analytical capabilities and expanding service offerings. - Management expressed confidence in medium- to long-term opportunities, citing positive enquiry trends, healthy demand visibility, and strong performance in pharma services, particularly in the U.S. market.